Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 12:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2329–2352 of 35,409 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: alone Clear all

Conditions: Lung Neoplasms, Ovarian Neoplasms, Cervix Neoplasms, Renal Neoplasms
Interventions: docetaxel, tariquidar, 99mTc-sestamibi imaging; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Syphilis
Interventions: Benzathine Penicillin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 10
States / cities: Birmingham, Alabama • Atlanta, Georgia • Indianapolis, Indiana + 7 more

Conditions: Heart Disease, Myocardial Infarction, Acute Myocardial Infarction
Interventions: Reteplase 10 Units (U) plus a second dose of reteplase 10 U, Reteplase 10 U, Urgent Percutaneous Coronary Intervention (PCI), Primary Percutaneous Coronary Intervention (PCI); Drug · Procedure
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Healthy Volunteers
Interventions: [^14C]-LY3023703; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer, Squamous Non-Small Cell Lung Cancer
Interventions: AZD8205, AZD8205 and AZD2936 (Rilvegostomig), AZD8205 and AZD5305 (saruparib), AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig), AZD8205 in combination with AZD9574, AZD8205 in combination with AZD9574 plus rilvegostomig (AZD2936); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 14
States / cities: Duarte, California • Irvine, California • Santa Monica, California + 11 more

Conditions: Contraceptive Use, Unintended Pregnancy
Interventions: Reproductive Life Planning (RLP), Contraceptive Action Planning, Contraception information; Behavioral
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 987 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Pain
Interventions: fNIRS; Device
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 1 Month to 16 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Cluster Headache
Interventions: C213 Microneedle System, Placebo; Drug
Lead sponsor: Zosano Pharma Corporation; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 12
States / cities: Los Angeles, California • Palo Alto, California • Santa Monica, California + 9 more

Conditions: Syncope, Vasovagal
Interventions: CPC - Capsaicin, Phenylephrine, Caffeine, Tilt Table Test, Placebo; Drug · Diagnostic Test
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 50 Years
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Unilateral Cryptorchidism
Interventions: Single-stage Fowler-Stephens orchidopexy (FSO), Two-stage Fowler-Stephens orchidopexy (FSO); Procedure
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 4 Months to 36 Months · Male only
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Necrotizing Enterocolitis
Interventions: hydrocortisone, placebo; Drug
Lead sponsor: Endeavor Health; Other
Eligibility: 0 Days to 6 Months
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 2
States / cities: Chicago, Illinois • Evanston, Illinois

Conditions: Colorectal Disorders, Anorectal Disorder, Patient Satisfaction, Pain, Postoperative, Opioid Use, Opioid Abuse, Opioid Dependence
Interventions: ReCOVER Enhanced Recovery Protocol; Procedure
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy, Hepatic Impairment
Interventions: Mirdametinib (MEK Inhibitor); Drug
Lead sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • San Antonio, Texas

Conditions: Salivary Gland Cancer, Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Cancer, Adenoid Cystic Carcinoma
Interventions: Ivonescimab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Melanoma (Skin)
Interventions: NY-ESO-1 157-165 (165V), Nivolumab, gp100:280-288 (288V), Montanide ISA 51 vegetable grade (VG), Ipilimumab, Apheresis Procedure; Biological · Drug · Procedure
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 16 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2023
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Alcohol Use Disorder, Social Anxiety Disorder
Interventions: Fully integrated treatment, Stand-alone Intensive Outpatient Program; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Healthy
Interventions: Fadraciclib; Drug
Lead sponsor: Cyclacel Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Participants
Interventions: Axatilimab; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Edematous Fibrosclerotic Panniculopathy
Interventions: Previously Treated with EN3835; Biological
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 5
States / cities: Clearwater, Florida • Coral Gables, Florida • Washington, Missouri + 2 more

Conditions: X-Linked Retinitis Pigmentosa
Interventions: BIIB112; Biological
Lead sponsor: Biogen; Industry
Eligibility: 10 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 5
States / cities: Gainesville, Florida • Miami, Florida • Portland, Oregon + 2 more

Conditions: Prescription Drug Abuse (Not Dependent)
Interventions: Oxycodone Medication First, Placebo First; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 30 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Aging Hands
Interventions: Transcutaneous electrical nerve stimulation (TENS), Familiarization; Behavioral
Lead sponsor: University of Colorado, Boulder; Other
Eligibility: 54 Years to 89 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Boulder, Colorado

Conditions: Aging
Interventions: Rapamycin (Tablets), Prolon diet; Drug · Dietary Supplement
Lead sponsor: The Christ Hospital; Other
Eligibility: 50 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Alzheimer Disease, Cognitive Dysfunction, Dementia
Interventions: JNJ-63733657, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 55 Years to 80 Years
Enrollment: 523 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 55
States / cities: Birmingham, Alabama • Phoenix, Arizona • Irvine, California + 47 more

Search by objective public record fields.

Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer

Phase 4 Comparative Trial of Benzathine Penicillin G for Treatment of Early Syphilis in Subjects With or Without HIV Infection

Pre-hospital Administration of Thrombolytic Therapy With Urgent Culprit Artery Revascularization

A Study of [14C]-LY3023703 in Healthy Participants

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

MyNewOptions: An Online Study of Reproductive Life Planning and Contraceptive Action Planning

Functional Near Infrared Spectroscopy to Detect Pain in Young Children Under General Anesthesia

Double-Blind Comparison of the Efficacy and Safety of C213 to Placebo for the Acute Treatment of Cluster Headaches

The Effect of CPC on Aborting Tilt Induced Syncope in Patients With a History of Vasovagal Syncope or Near Syncope

Orchidopexy Randomized Clinical Assessment

Anti-inflammatory Treatment at the Onset of Necrotizing Enterocolitis (NEC) in Preterm Infants

A Multimodal Enhanced Recovery Program in Anorectal Surgery

Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib

A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers

Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma

Treatment for Comorbid Social Anxiety and Alcohol Use Disorders.

Absorption, Metabolism, and Excretion of CYC065 in Healthy Male Subjects

A Study to Evaluate a Single-Dose Subcutaneous Axatilimab Compared With Intravenous Axatilimab in Healthy Participants

Durability and Safety of EN3835 in the Treatment of EFP (Cellulite) in Women

A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112

Influence of Medication on Functional Connectivity

Neural Substrates Underlying Adaptations in Manual Dexterity of Older Adults

A Pilot Study on Reverse Aging (The REVERSE Study)

A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease